Epidemiology and natural history of nonalcoholic fatty liver disease
SK Satapathy, AJ Sanyal - Seminars in liver disease, 2015 - thieme-connect.com
The epidemic of obesity has resulted in a parallel incremental burden of nonalcoholic fatty
liver disease (NAFLD) worldwide. Nonalcoholic fatty liver disease includes a spectrum of …
liver disease (NAFLD) worldwide. Nonalcoholic fatty liver disease includes a spectrum of …
[HTML][HTML] Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management
G Cholankeril, R Patel, S Khurana… - World journal of …, 2017 - ncbi.nlm.nih.gov
With the prevalence of hepatitis C virus expected to decline, the proportion of hepatocellular
carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) is anticipated to increase …
carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) is anticipated to increase …
Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta‐analysis
S Young, R Tariq, J Provenza… - Hepatology …, 2020 - Wiley Online Library
Data on prevalence and profile of nonalcoholic fatty liver disease (NAFLD) among
individuals who are lean (normal body mass index) is unclear. Published data from studies …
individuals who are lean (normal body mass index) is unclear. Published data from studies …
Impact of COVID‐19 pandemic on liver transplantation and alcohol‐associated liver disease in the USA
Involvement of TIGIT in Natural Killer Cell Exhaustion and I... : Hepatology Involvement of
TIGIT in Natural Killer Cell Exhaustion and Immune Escape in Patients and Mouse Model With …
TIGIT in Natural Killer Cell Exhaustion and Immune Escape in Patients and Mouse Model With …
Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome
Conclusions SARS‐CoV‐2 vaccination can be associated with liver injury. Corticosteroid
therapy may be beneficial in those with immune‐mediated features or severe hepatitis …
therapy may be beneficial in those with immune‐mediated features or severe hepatitis …
[HTML][HTML] Prevalence, risk factors, and outcomes of hospitalized patients with coronavirus disease 2019 presenting as acute pancreatitis
S Inamdar, PC Benias, Y Liu, DV Sejpal… - …, 2020 - ncbi.nlm.nih.gov
Methods This is a retrospective observational cohort study of patients 18 years or older
admitted to 12 hospitals within the Northwell Health System from March 1, 2020, to June 1 …
admitted to 12 hospitals within the Northwell Health System from March 1, 2020, to June 1 …
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
SA Harrison, Z Goodman, A Jabbar… - Journal of …, 2020 - journal-of-hepatology.eu
Background & Aims Non-alcoholic steatohepatitis (NASH) is characterized by hepatocyte
steatosis, ballooning, and lobular inflammation which may lead to fibrosis. Lipotoxicity …
steatosis, ballooning, and lobular inflammation which may lead to fibrosis. Lipotoxicity …
Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non‐alcoholic steatohepatitis
SK Satapathy, P Sakhuja, V Malhotra… - Journal of …, 2007 - Wiley Online Library
Abstract Background and Aim: Inhibition of tumor necrosis factor (TNF)‐α is a logical
approach to manage patients with non‐alcoholic steatohepatitis (NASH). Pentoxifylline …
approach to manage patients with non‐alcoholic steatohepatitis (NASH). Pentoxifylline …
Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study
Background & Aims There is controversy over the effects of direct-acting antiviral (DAA)
therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) …
therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) …
[HTML][HTML] Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis
Abnormal liver enzymes are seen in 20% of hospitalized patients with COVID-19. The
etiology of elevated liver enzymes is thought to be multifactorial including medications and …
etiology of elevated liver enzymes is thought to be multifactorial including medications and …